<DOC>
	<DOCNO>NCT00258830</DOCNO>
	<brief_summary>To describe safety Days 0 21 follow injection 2005-2006 formulation inactivate , split-virion influenza vaccine Fluzone subject age 18-59 year subject age ≥ 60 year . To describe immune response ( antibody hemagglutinin ) 21 day follow injection 2005-2006 formulation inactivate , split-virion influenza vaccine Fluzone , subject age 18-59 year subject age ≥ 60 year . To submit remain available serum Center Biologics Evaluation Research ( CBER ) analysis Food Drug Administration ( FDA ) , Center Disease Control Prevention ( CDC ) World Health Organization ( WHO ) support selection recommendation antigen strain subsequent influenza vaccine .</brief_summary>
	<brief_title>Safety Immunogenicity 2005-2006 Fluzone® Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Participant age 18 year old day inclusion . Participant able attend schedule visit comply study procedure entire duration study . Participant reasonably good health assess investigator . Participant willing able meet protocol requirement . Participant willing able give inform consent . For woman , inability bear child negative serum/urine pregnancy test . Selfreported allergy egg protein , chicken protein , one constituent vaccine , thimerosal formaldehyde . An acute illness without fever ( temperature ≥ 99.5°F oral ) 72 hour precede enrollment trial . Clinically significant finding vital sign ( include temperature ≥ 99.5°F oral ) review system . Selfreported history severe adverse event influenza vaccine . Laboratoryconfirmed influenza infection vaccination influenza 6 month precede enrollment study . Any vaccination 14 day precede enrollment study schedule Visit 1 Visit 3 . Vaccination plan 4 week follow trial vaccination . Participation interventional drug vaccine trial within 30 day precede enrollment study . Immunocompromising immunosuppressive therapy ( include systemic steroid use 2 week ) , cancer chemotherapy , radiation therapy time enrollment , plan period study , time within past 6 month . Receipt blood blood product within 3 month precede enrollment study . Diabetes mellitus require pharmacological control . Any condition opinion Investigator pose health risk subject enrol interfered evaluation vaccine . Person deprive freedom administrative court order ( legal medical guardian ) . For woman childbearing potential , positive urine pregnancy test , breast feeding , use medically approve form contraception duration trial . Current abuse alcohol drug addiction interfere subject 's ability comply trial procedure . Thrombocytopenia bleed disorder contraindicate intramuscular ( IM ) vaccination .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Influenza vaccine</keyword>
</DOC>